inclusion criteria: 1. adults, aged 40 - 90 years (inclusive) 2. acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. 3. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. 4. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). 5. participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. 6. participant is willing and able to follow all study procedures and assessments according to the study protocol. 7. participant is able to consume 60 ml of fluid orally twice daily. 8. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.

inclusion criteria: 1. adults, aged 40 - 90 years (inclusive) 2. acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. 3. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. 4. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). 5. participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. 6. participant is willing and able to follow all study procedures and assessments according to the study protocol. 7. participant is able to consume 60 ml of fluid orally twice daily. 8. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.

inclusion criteria: adults, aged 40 - 90 years (inclusive) acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. participant is willing and able to follow all study procedures and assessments according to the study protocol. participant is able to consume 60 ml of fluid orally twice daily. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.

inclusion criteria: adults, aged 40 - 90 years (inclusive) acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. participant is willing and able to follow all study procedures and assessments according to the study protocol. participant is able to consume 60 ml of fluid orally twice daily. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.

inclusion criteria: 1. adults, aged 40 - 90 years (inclusive) 2. acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. 3. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. 4. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). 5. participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. 6. participant is willing and able to follow all study procedures and assessments according to the study protocol. 7. participant is able to consume 60 ml of fluid orally twice daily. 8. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.

inclusion criteria: 1. adults, aged 40 - 90 years (inclusive) 2. acute onset (within 96 hours of the baseline visit) of two or more covid-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. 3. laboratory-confirmed sars-cov-2 infection as determined by positive pcr in a sample collected ≤ 96 hours prior to the baseline visit. 4. pgi-severity and cgi-severity assessments of 'mild', 'moderate, or 'severe' at the screening visit (e.g., cannot be 'normal'). 5. participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures. 6. participant is willing and able to follow all study procedures and assessments according to the study protocol. 7. participant is able to consume 60 ml of fluid orally twice daily. 8. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.